GILD News Alert Gilead Sciences (GILD) 101.90 02/14/2015 11:

New Post Public Reply Private Reply Replies (0) Message Board

Feb 14, 2015 at 12:24 PM

Gilead Sciences (GILD) 101.90 $GILD

3 Biotech Stocks I Love
Todd Campbell, The Motley Fool - Motley Fool - 16 mins ago
Source: Flickr user Simon & His Camera . Love is in the air, and that makes it the perfect time to confess my affection for three large-cap biotech stocks that market a slate of highly profitable, market-share leading therapies. Read on to...
BIIB: 391.66 (-0.45), GILD: 101.90 (+1.10), ABBV: 58.05 (+1.00), CELG: 115.88 (+0.16)

Gilead Fundamentals Appear Better Than The Stock 'Is Suggesting'
Leonard Yaffe - at Seeking Alpha - 18 mins ago

GILD: 101.90 (+1.10)

2 Small Biotech Stocks Dreaming Big in Hepatitis C
Todd Campbell and Michael Douglass, The Motley Fool - Motley Fool - 1 hr 20 mins ago
Hepatitis C treatment has progressed by leaps and bounds in the past few years, and appears to be accelerating even more quickly now. Cure rates have increased, treatment times are plummeting, and side effects are falling away. Is now the time to...
JNJ: 99.62 (+1.18), VRTX: 113.66 (+4.03), ISIS: 63.86 (-0.43), ALNY: 95.54 (+1.67), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), SHPG: 239.82 (+6.11), MRK: 58.81 (-0.07), CVS: 102.63 (-0.37), ABBV: 58.05 (+1.00), RGLS: 16.85 (-0.13)

Achillion Pharmaceuticals: High Marketing Potential With Long-Term Prospects
Steven Giardino - at Seeking Alpha - 1 hr 46 mins ago

GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), MRK: 58.81 (-0.07), ABBV: 58.05 (+1.00)

1 Number Shows Why Gilead Sciences, Inc. Shareholders Should Be Thrilled Right Now
Todd Campbell, The Motley Fool - Motley Fool - Sat Feb 14, 7:04AM CST
Source: Gilead Sciences Thanks to launching the billion dollar blockbuster hepatitis C drugs Sovaldi and Harvoni, Gilead Sciences posted some pretty eye-popping numbers in 2014. In fact, these numbers are so impressive that I'm going to reel...
ESRX: 84.90 (+0.40), GILD: 101.90 (+1.10), ABBV: 58.05 (+1.00)

Dividend Growth: Is It Really The Right Strategy For You?
Adam Aloisi - at Seeking Alpha - Fri Feb 13, 5:42PM CST

KO: 41.99 (-0.18), T: 34.66 (+0.05), GILD: 101.90 (+1.10), STZ: 113.03 (-0.48), DIS: 104.17 (+0.59), PG: 85.90 (-0.13), O: 52.01 (+0.32), ARCP: 9.40 (+0.06), GOOG: 549.01 (+6.08), AAPL: 127.08 (+0.62), PCLN: 1,103.37 (+11.42), CSCO: 29.43 (-0.03), NRF: 18.65 (+0.12)

Netflix, Amazon Lead Q4 With Biggest Earnings Beat
at Investor's Business Daily - Fri Feb 13, 3:41PM CST
The health care and technology sectors in the S&P 500 have the highest percentage of companies reporting fourth-quarter earnings above analyst consensus estimates. In the health care sector, 91% of companies have beat the consensus estimates of...
NFLX: 466.10 (+9.37), AMZN: 381.83 (+4.66), EA: 56.39 (+0.20), MPC: 103.48 (+2.08), GILD: 101.90 (+1.10), KLAC: 63.64 (-0.23), JNPR: 23.84 (+0.19)

Seeking Alpha's Biotech Weekly: Crush-Proof Pfizer, Achillion's HCV Crusher, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 13, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
VRX: 167.00 (-0.50), ACT: 285.37 (+3.71), MDT: 75.26 (+0.33), XON: 39.30 (+1.05), CTIC: 2.23 (-0.02), PFNX: 12.45 (+0.29), JNJ: 99.62 (+1.18), ANTM: 141.05 (-0.95), NVAX: 8.80 (+0.40), SHPG: 239.82 (+6.11), ABBV: 58.05 (+1.00), TBPH: 18.51 (+0.28), SNY: 49.42 (+0.82), ALQA: 6.14 (+0.09), REGN: 402.40 (+0.66), ONCY: 0.51 (+0.02), PFE: 34.64 (-0.23), SLXP: 152.35 (+3.17), EPRS: 7.67 (+0.67), AMGN: 153.48 (+0.30), NKTR: 13.54 (-0.14), ZTS: 45.46 (-0.33), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), GERN: 3.03 (unch)

Midday Glance: Biotechnology companies
AP - Fri Feb 13, 12:23PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
GILD: 101.90 (+1.10), AMGN: 153.48 (+0.30), CELG: 115.88 (+0.16)

Early Glance: Biotechnology companies
AP - Fri Feb 13, 10:05AM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
GILD: 101.90 (+1.10), AMGN: 153.48 (+0.30), CELG: 115.88 (+0.16)

Gilead: No Reason To Panic Here
Bret Jensen - at Seeking Alpha - Fri Feb 13, 7:54AM CST

GILD: 101.90 (+1.10), AAPL: 127.08 (+0.62)

1 Sentence That Tells You Everything You Need to Know About Each of These 10 Big Pharma Earnings Rep
Sean Williams, The Motley Fool - Motley Fool - Fri Feb 13, 7:02AM CST
Source: AstraZeneca. Earnings season is more than halfway over, and it hasn't been easy to keep pace with hundreds upon hundreds of earnings reports, sometimes all hitting within the same day. Much of the healthcare sector, especially big...
BIIB: 391.66 (-0.45), JNJ: 99.62 (+1.18), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), AZN: 69.96 (+0.20), PFE: 34.64 (-0.23), AMGN: 153.48 (+0.30), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), CELG: 115.88 (+0.16)

5 Things CVS Health's Management Wants You to Know
Keith Speights, The Motley Fool - Motley Fool - Fri Feb 13, 6:02AM CST
Make it three in a row for CVS Health ! The large pharmacy retailer and pharmacy benefits manager beat earnings expectations for the third consecutive quarter when it announced fourth-quarter results on Tuesday. Company executives discussed those...
GILD: 101.90 (+1.10), CVS: 102.63 (-0.37)

Gilead Management's Conservative Guidance Offers Investors A Dip To Buy Into
BMD Asset Management and Research - at Seeking Alpha - Thu Feb 12, 11:34PM CST

GILD: 101.90 (+1.10)

Final Glance: Biotechnology companies
AP - Thu Feb 12, 5:03PM CST
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
GILD: 101.90 (+1.10), AMGN: 153.48 (+0.30), CELG: 115.88 (+0.16)

Gilead Sciences and Beryllium Publish the Structural Basis for HCV RNA Replication in Science
Business Wire - Thu Feb 12, 1:05PM CST
In this week's issue of Science, researchers at Gilead Sciences, Inc. (Nasdaq:GILD) and Beryllium reveal new details about how the hepatitis C virus (HCV) replicates its genome. HCV is estimated to affect 150-200 million people worldwide and is the major cause of liver transplantation in the US. HCV uses RNA as genetic material which must be replicated in order to propagate the viral infection. Appleby et al. determined high resolution X-ray crystal structures of the HCV polymerase during the process of RNA replication, shedding light on the replication complex after 15 years of speculation. These molecular snap-shots unveil the NS5B catalytic mechanism in successive steps from the opening of the fist-like polymerase through the rapid RNA polymerization stage known as elongation. "For the first time we can see at the atomic level how the HCV polymerase interacts with the genomic RNA template, replicating RNA, and nucleotide substrates," said corresponding author Thomas Edwards of Beryllium.
GILD: 101.90 (+1.10)

AbbVie Seeks Japanese Approval for HCV Cocktail Treatment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 12, 12:30PM CST
AbbVie (ABBV) filed a new drug application with the Japanese Ministry of Health, Labour and Welfare for its experimental, all-oral, ribavirin and interferon free hepatitis C virus treatment.
ESRX: 84.90 (+0.40), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), ABBV: 58.05 (+1.00)

AbbVie files NDA in Japan for 12-week once-daily HCV combo med
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 10:25AM CST

GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), ABBV: 58.05 (+1.00), ENTA: 33.30 (-0.44)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Truck Drivers USA & Career Driver Unveil New Driver Agent

Revolutionizing Driver-Carrier Connections In today's cranking transportation scene, Truck Drivers USA (TDUSA) and Career Driver have taken a bold step to change up the driver recruitment game. They've launched what's being labeled as the first 'driver agent' within the Career Driver mobile app. It's the talk of the town in Sherwood, Arkansas, these days. This isn't just...

Simple Home Upgrades That Boost Value Fast

Transform Your Home's Curb Appeal Without Breaking The Bank Every homeowner knows that feeling when you look at your house one day and think, "This could use a little something." Say you're strolling through a neighborhood in Fulton, N.Y., and notice a gem. It's not a brand new build, but it gleams with character. You bet it's had a few smart touches that could apply...

New Data on SKYRIZI Offers Hope for Crohn's Patients

Treating Crohn's: New Hope on the Horizon Folks, let me tell you, the landscape for treating Crohn's disease just got a bit more interesting. AbbVie's Phase 3 AFFIRM study has brought some attention-grabbing data on the table, showcasing the potential of their drug, SKYRIZI® (risankizumab-rzaa). This ain't just another run-of-the-mill study; these results could be a...

Gourmia Introduces Ceramic-Coated Air Fryer at Costco

A New Era for Home Cooking with Gourmia Stepping into the kitchen appliances arena with a dash of innovation, Gourmia has launched its first ceramic-coated air fryer, and it’s weaving its way exclusively onto the shelves of Costco. Now, it’s not just about frying anymore; it’s about adding style, efficiency, and a touch of healthy living to your countertop. But much...

Dr. Anderson’s Journey: Leadership with Faith and Service

A Life Shaped by Service Dr. Howard Anderson isn't just another name in a glossy award roster—he's a powerhouse of leadership, a chaplain of compassion, and a soldier in spirit. Honored as a Pinnacle Professional Member of The Inner Circle of Excellence, his recognition feels less like an accolade and more like a testament to a life committed to serving others. The...

Canada and Ukraine Fortify Defense with UGV Partnership

New Defense Fronts: Canada and Ukraine Join Forces October 13, 2026, marks an important day in Ottawa's defense narrative with Dominion Dynamics and Ukraine's TENCORE kicking off a robust partnership. They're not just collaborating; they're plugging into each other's strengths to build TerMIT uncrewed ground vehicles (UGVs) on Canadian soil. These aren't gizmos you find...

Marshall Goldman Expands Footprint with Marino Acquisition

Revving Up in Florida: Marshall Goldman's Strategic Leap If you're tuned into the luxury car scene, you probably already heard Marshall Goldman is making moves into Florida. Buying Marino Performance Motors of West Palm Beach isn't just another notch on their belt—it's a strategic leap into their second-largest market. This ain't merely about showroom floor space. Think...

Cogent Communications' Q3 2026 Earnings Call Details

Cue the Countdown: Cogent’s Earnings Call Looms Another quarter rolls by, and with it comes Cogent Communications' chance to strut—or stumble—before the crowd. Their third-quarter earnings call on November 5, 2026, is like the opening bell for a stock that's zipped through more ups and downs than a tired bullfighter's routine. What the call reveals on that crisp...

A1 Refrigeration Keeps East Texas Homes Comfortable Year-Round

Homeowners in East Texas would agree: the last thing you want is your HVAC system throwing a tantrum when you're in the thick of a scorching summer or a biting winter. That's where A1 Refrigeration & Air Conditioning steps in, making sure folks in Jasper, Brookeland, and Kirbyville aren't left sweating bullets or shivering in their boots. Preventive Maintenance: A...

Tessa AI: Revolutionizing Biomedical Research with AI

Shaking Up Research Evaluation When Siensmetrica decided it was high time for a name change, morphing into Tessa AI wasn't just a cosmetic shift. It was a nod to what stakeholders were already calling it and laid the ground for a broader mission statement. They're not sitting on their hands; they're crafting tools that tackle the scientific life cycle from start to...